OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.

Autor: Linhares Y; Baptist Health, Miami Cancer Institute, Miami, FL., Freytes CO; Sarah Cannon Transplant & Cellular Therapy Program at Methodist Hospital, San Antonio, TX., Cherry M; Department of Hematology Oncology/Medical Oncology, Atlantic Health System, Carol Simon Cancer Center, Morristown, NJ., Bachier C; Sarah Cannon Transplant & Cellular Therapy Program at Methodist Hospital, San Antonio, TX., Maris M; Department of Hematology/Oncology, Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, CO., Hoda D; Intermountain Healthcare, Loveland Clinic for Blood Cancer Therapy, Salt Lake City, UT., Varela JC; Advent Health, Orlando, FL., Bellomo C; New York Oncology Hematology, Albany, NY., Cross S; Virginia Oncology Associates, Norfolk, VA., Essell J; Oncology Hematology Care, Cincinnati, OH., Fanning S; Prisma Health, Greenville, SC., Terebelo H; Ascension Providence Hospital, Southfield, MI., Yimer H; Texas Oncology-Tyler, Tyler, TX., Courtright J; Texas Oncology, Medical City Dallas, Dallas, TX., Sharman JP; Willamette Valley Cancer Institute, Eugene, OR., Kostic A; Bristol Myers Squibb, Seattle, WA., Vedal M; Bristol Myers Squibb, Seattle, WA., Ogasawara K; Bristol Myers Squibb, Princeton, NJ., Avilion A; Bristol Myers Squibb, Seattle, WA., Espinola R; Bristol Myers Squibb, San Diego, CA., Yuan B; Bristol Myers Squibb, Princeton, NJ., Mattar B; Cancer Center of Kansas, Wichita, KS.

Publikováno v: Blood advances [Blood Adv] 2024 Dec 10; Vol. 8 (23), pp. 6114-6126.

Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

Autor: Basso, AC, Bonvehi, P, Cerana, S, Dictar, MO, Campbell, P, Playford, G, Sasadeusz, J, Maertens, J, Poire, X, Sellesag, D, Schots, R, Theunissen, K, Willems, E, Alves, RS, Camargo, JFC, Castro, NS, Maria Fogliatto, L, Rodrigo, O, Courture, F, McGeer, A, Miller, M, Combariza, JF, Sossa, CL, Velez, JD, Nemet, D, Ostojic Kolonic, S, Jebavy, L, Mayer, J, Novak, J, Pohlreich, D, Maldonado, B, Gastinne, T, Karlin, L, Launay, O, Cornely, OA, Duerk, HA, Haenel, M, Heinz, W, Kaufmann, M, Panse, J, Teschner, D, Verbeek, M, Wulf, G, Aviv, F, Grisariu, S, Nagler, A, Yeshurun, M, Bosi, A, Corradini, P, Martinelli, G, Onida, F, Rambaldi, A, Velardi, A, Trociukas, I, Gomez, AD, Wondergem, MJ, Ypma, PF, Fanilla, E, Moreno Larrea, MDC, Abecasis, MM, Ferreira, RB, Geraldes, C, Castro, J, Afanasyev, BV, Kruchkova, IV, Zaritskiy, AY, Cheong, JW, Kim, SJ, Lee, DG, Yoon, SS, Aguado Bueno, B, Jarque Ramos, I, Solano Vercet, C, Cherif, H, Ljungman, P, Vaht, K, Cook, G, Kanfer, E, Milligan, DW, Parker, A, Akard, L, Bachier, C, Ball, ED, Betts, FR, Braunschweig, I, Brown, JM, Carroll, MP, Chandrasekar, PH, Collins, R, Cooper, B, Craig, M, D'Cunha, N, Donato, ML, Essell, J, Flomenberg, P, Freifeld, A, Freytes, C, Guarino, MJ, Hall, MC, Heimenz, JW, High, KP, Isola, LM, Kaminer, L, Klein, LM, Janakiraman, N, Kane, K, Komanduri, K, Krijanovski, OI, Lawrence, SJ, Leis, JF, Lill, M, Longo, WL, Lynch, JP, Mattar, BI, Mehta, J, Mullane, KM, Nathan, S, Papanicolaou, GA, Pergam, SA, Roy, V, Rybka, W, Safah, H, Saltzman, D, Segal, GM, Selby, GB, Schuster, MW, Shoham, S, Sloan, JM, Strasfeld, LM, Styler, M, Sullivan, K, Tse, W, Vance, EA, Winston, DJ, Yanovich, S, Winston, Drew J, Mullane, Kathleen M, Cornely, Oliver A, Boeckh, Michael J, Brown, Janice Wes, Pergam, Steven A, Trociukas, Igoris, Žák, Pavel, Craig, Michael D, Papanicolaou, Genovefa A, Velez, Juan D, Panse, Jens, Hurtado, Kimberly, Fernsler, Doreen A, Stek, Jon E, Pang, Lei, Su, Shu-Chih, Zhao, Yanli, Chan, Ivan S F, Kaplan, Susan S, Parrino, Janie, Lee, Ingi, Popmihajlov, Zoran, Annunziato, Paula W, Arvin, Ann

Publikováno v: In The Lancet 26 May-1 June 2018 391(10135):2116-2127

A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help.

Autor: Curran KJ; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Nikiforow S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Bachier C; Sarah Cannon Transplant and Cellular Therapy Program, St. David's Austin Medical Center, Austin, TX., Hsu YM; Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA., Maloney D; Division of Hematology and Oncology Fred Hutchinson Cancer Research Center, Seattle WA., Maus MV; Cellular Immunotherapy Program Massachusetts General Hospital, Boston MA., McCarthy P; Department of Medicine, Transplant and Cellular Therapy Program Roswell Park Comprehensive Cancer Center, Buffalo, NY., Porter D; Division of Hematology/Oncology, Department of Medicine and Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA., Shi P; New York Blood Center Clinical Apheresis and Cellular Therapy Laboratory, New York, NY., Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., William B; OhioHealth Blood and Marrow Transplant Program, OhioHealth, Columbus, OH., Wacker K; Foundation for the Accreditation of Cellular Therapy, Omaha, NE., Warkentin P; Foundation for the Accreditation of Cellular Therapy, Omaha, NE.; Pathology/Microbiology, University of Nebraska Medical Center, Omaha, NE., Heslop HE; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX.

Publikováno v: Blood advances [Blood Adv] 2024 Feb 27; Vol. 8 (4), pp. 1053-1061.

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.

Autor: Roddie C; Cancer Institute, University College London, London, United Kingdom.; Department of Haematology, University College London Hospital, London, United Kingdom., Lekakis LJ; Department of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Marzolini MAV; Department of Haematology, University College London Hospital, London, United Kingdom., Ramakrishnan A; Department of Hematology, St David's South Austin Medical Center, Austin, TX., Zhang Y; Department of Haematology, Autolus Ltd, London, United Kingdom., Hu Y; Department of Haematology, Autolus Ltd, London, United Kingdom., Peddareddigari VGR; Department of Haematology, Autolus Ltd, London, United Kingdom., Khokhar N; Department of Haematology, Autolus Ltd, London, United Kingdom., Chen R; Department of Haematology, Autolus Ltd, London, United Kingdom., Basilico S; Department of Haematology, Autolus Ltd, London, United Kingdom., Raymond M; Department of Haematology, Autolus Ltd, London, United Kingdom., Vargas FA; Department of Haematology, Autolus Ltd, London, United Kingdom., Duffy K; Department of Haematology, Autolus Ltd, London, United Kingdom., Brugger W; Department of Haematology, Autolus Ltd, London, United Kingdom., O'Reilly MA; Department of Haematology, University College London Hospital, London, United Kingdom., Wood L; Department of Haematology, University College London Hospital, London, United Kingdom., Linch DC; Cancer Institute, University College London, London, United Kingdom., Peggs KS; Cancer Institute, University College London, London, United Kingdom.; Department of Haematology, University College London Hospital, London, United Kingdom., Bachier C; Department of Hematology, Methodist Hospital, San Antonio, TX., Budde EL; Department of Hematology, City of Hope National Medical Centre, Duarte, CA., Lee Batlevi C; Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY., Bartlett N; Department of Hematology, Washington University School of Medicine, St Louis, MO., Irvine D; Department of Haematology, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Tholouli E; Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom., Osborne W; Department of Haematology, Freeman Hospital, Newcastle, United Kingdom., Ardeshna KM; Department of Haematology, University College London Hospital, London, United Kingdom., Pule MA; Cancer Institute, University College London, London, United Kingdom.; Department of Haematology, Autolus Ltd, London, United Kingdom.

Publikováno v: Blood [Blood] 2023 May 18; Vol. 141 (20), pp. 2470-2482.

The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy.

Autor: Peaytt R; 23769TriStar Centennial Medical Center, Nashville, TN, USA., Parsons LB; 23769TriStar Centennial Medical Center, Nashville, TN, USA., Siler D; 23769TriStar Centennial Medical Center, Nashville, TN, USA., Matthews R; 23769TriStar Centennial Medical Center, Nashville, TN, USA., Li B; 14360Emory Healthcare, Atlanta, GA, USA., Bell D; 233695Belmont University College of Pharmacy, Nashville, TN, USA., Bachier C; 10606Sarah Cannon Cancer Center, Nashville, TN, USA., Pantin J; 10606Sarah Cannon Cancer Center, Nashville, TN, USA., Berdeja J; 219711Tennessee Oncology, Nashville, TN, USA., Flinn I; 219711Tennessee Oncology, Nashville, TN, USA., Donnellan W; 219711Tennessee Oncology, Nashville, TN, USA., Battiwalla M; 10606Sarah Cannon Cancer Center, Nashville, TN, USA.

Publikováno v: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2023 Jan; Vol. 29 (1), pp. 45-51. Date of Electronic Publication: 2021 Nov 24.